

# Enhanced Annual Drug List Updates

April 2026

| TRADE NAME (generic name)   | Brand/Generic Product | Description of Change      |
|---|-----------------------|----------------------------|
| ANDEMBRY (garadacimab-gxii soln auto-injector 200 mg/1.2ml)           | Brand                 | Addition, Preferred Status |
| DAWNZERA (donidalorsen sodium subcutaneous soln auto-inj 80 mg/0.8ml) | Brand                 | Addition, Preferred Status |
| KERENDIA (finerenone tab 40 mg)                                       | Brand                 | Addition, Preferred Status |
| OMVOH (mirikizumab-mrkz subcutaneous sol prefill syringe 200 mg/2ml)  | Brand                 | Addition, Preferred Status |
| OMVOH (mirikizumab-mrkz subcutaneous soln auto-injector 200 mg/2ml)   | Brand                 | Addition, Preferred Status |
| PAZOPANIB HYDROCHLORIDE (pazopanib hcl tab 400 mg (base equiv))       | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 10 mg/0.2ml)               | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 12.5 mg/0.25ml)            | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 15 mg/0.3ml)               | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 17.5 mg/0.35ml)            | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 20 mg/0.4ml)               | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 22.5 mg/0.45ml)            | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 25 mg/0.5ml)               | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 30 mg/0.6ml)               | Brand                 | Addition, Preferred Status |
| RASUVO (methotrexate soln pf auto-injector 7.5 mg/0.15ml)             | Brand                 | Addition, Preferred Status |
| VRAYLAR (cariprazine hcl cap 0.5 mg (base equivalent))                | Brand                 | Addition, Preferred Status |
| VRAYLAR (cariprazine hcl cap 0.75 mg (base equivalent))               | Brand                 | Addition, Preferred Status |
| WEGOVY (semaglutide (weight management) tab 1.5 mg)                   | Brand                 | Addition, Preferred Status |
| WEGOVY (semaglutide (weight management) tab 25 mg)                    | Brand                 | Addition, Preferred Status |
| WEGOVY (semaglutide (weight management) tab 4 mg)                     | Brand                 | Addition, Preferred Status |
| WEGOVY (semaglutide (weight management) tab 9 mg)                     | Brand                 | Addition, Preferred Status |
| YEZTUGO (lenacapavir sodium subcutaneous soln 463.5 mg/1.5ml)         | Brand                 | Addition, Preferred Status |
| YEZTUGO (lenacapavir sodium tab 300 mg)                               | Brand                 | Addition, Preferred Status |
| ZURNAI (nalmeferene hcl soln auto-injector 1.5 mg/0.5ml (base equiv)) | Brand                 | Addition, Preferred Status |

Blue Cross and Blue Shield of Illinois, a Division of Health Care Service Corporation, a Mutual Legal Reserve Company, an Independent Licensee of the Blue Cross and Blue Shield Association. Prime Therapeutics LLC is a separate company BCBSIL contracts with to provide pharmacy solutions. BCBSIL, as well as several independent Blue Cross and Blue Shield Plans, has an ownership interest in Prime Therapeutics.